Abbvie Inc Stock Performance
| ABBV Stock | USD 183.08 1.94 1.07% |
The firm shows a Beta (market volatility) of 0.17, which signifies not very significant fluctuations relative to the market. As returns on the market increase, AbbVie's returns are expected to increase less than the market. However, during the bear market, the loss of holding AbbVie is expected to be smaller as well. At this point, AbbVie Inc has a negative expected return of -0.0866%. Please make sure to confirm AbbVie's potential upside, and the relationship between the jensen alpha and rate of daily change , to decide if AbbVie Inc performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days AbbVie Inc has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly stable fundamental drivers, AbbVie is not utilizing all of its potentials. The latest stock price fuss, may contribute to near-short-term losses for the sophisticated investors. ...more
Actual Historical Performance (%)
One Day Return 1.07 | Five Day Return 5.01 | Year To Date Return 14.55 | Ten Year Return 164.91 | All Time Return 423.09 |
Forward Dividend Yield 0.0358 | Payout Ratio 0.5767 | Forward Dividend Rate 6.56 | Dividend Date 2025-02-14 | Ex Dividend Date 2025-01-15 |
1 | AbbVies Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio | 11/12/2024 |
| AbbVie dividend paid on 15th of November 2024 | 11/15/2024 |
3 | AbbVie Inc. Shares Acquired by Quest Partners LLC | 11/19/2024 |
4 | Which Is A Better Pick JNJ Stock Or AbbVie | 11/21/2024 |
5 | AbbVie upgraded to outperform by Leerink on recent sell-off | 11/22/2024 |
6 | JJ Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC | 11/25/2024 |
7 | Muscle Relaxant Drugs Market is expected to generate a revenue of USD 6.59 Billion by 2031, Globally, at 5.4 percent CAGR Verified Market Research | 11/26/2024 |
8 | AbbVie Inc. Position Reduced by Baldwin Investment Management LLC | 11/27/2024 |
| Begin Period Cash Flow | 9.2 B | |
| Total Cashflows From Investing Activities | -2 B |
AbbVie |
AbbVie Relative Risk vs. Return Landscape
If you would invest 19,611 in AbbVie Inc on August 31, 2024 and sell it today you would lose (1,303) from holding AbbVie Inc or give up 6.64% of portfolio value over 90 days. AbbVie Inc is currently does not generate positive expected returns and assumes 2.0893% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of stocks are less volatile than AbbVie, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
AbbVie Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for AbbVie's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as AbbVie Inc, and traders can use it to determine the average amount a AbbVie's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0414
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABBV |
Estimated Market Risk
| 2.09 actual daily | 18 82% of assets are more volatile |
Expected Return
| -0.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average AbbVie is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of AbbVie by adding AbbVie to a well-diversified portfolio.
AbbVie Fundamentals Growth
AbbVie Stock prices reflect investors' perceptions of the future prospects and financial health of AbbVie, and AbbVie fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on AbbVie Stock performance.
| Return On Equity | 0.56 | ||||
| Return On Asset | 0.0772 | ||||
| Profit Margin | 0.09 % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 387.32 B | ||||
| Shares Outstanding | 1.77 B | ||||
| Price To Earning | 21.28 X | ||||
| Price To Book | 53.64 X | ||||
| Price To Sales | 5.83 X | ||||
| Revenue | 54.32 B | ||||
| Gross Profit | 41.53 B | ||||
| EBITDA | 17.31 B | ||||
| Net Income | 4.87 B | ||||
| Cash And Equivalents | 11.88 B | ||||
| Cash Per Share | 6.72 X | ||||
| Total Debt | 59.38 B | ||||
| Debt To Equity | 4.37 % | ||||
| Current Ratio | 0.93 X | ||||
| Book Value Per Share | 3.41 X | ||||
| Cash Flow From Operations | 22.84 B | ||||
| Earnings Per Share | 2.87 X | ||||
| Market Capitalization | 323.53 B | ||||
| Total Asset | 134.71 B | ||||
| Retained Earnings | (1000 M) | ||||
| Working Capital | (4.84 B) | ||||
| Current Asset | 16.31 B | ||||
| Current Liabilities | 10.89 B | ||||
About AbbVie Performance
Evaluating AbbVie's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if AbbVie has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if AbbVie has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 73.29 | 92.91 | |
| Return On Tangible Assets | 0.10 | 0.10 | |
| Return On Capital Employed | 0.13 | 0.22 | |
| Return On Assets | 0.04 | 0.03 | |
| Return On Equity | 0.47 | 0.65 |
Things to note about AbbVie Inc performance evaluation
Checking the ongoing alerts about AbbVie for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for AbbVie Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| AbbVie Inc generated a negative expected return over the last 90 days | |
| AbbVie Inc currently holds 59.38 B in liabilities with Debt to Equity (D/E) ratio of 4.37, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. AbbVie Inc has a current ratio of 0.91, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about AbbVie's use of debt, we should always consider it together with its cash and equity. | |
| AbbVie Inc has a strong financial position based on the latest SEC filings | |
| About 73.0% of AbbVie shares are held by institutions such as insurance companies | |
| On 15th of November 2024 AbbVie paid $ 1.55 per share dividend to its current shareholders | |
| Latest headline from thelincolnianonline.com: AbbVie Inc. Position Reduced by Baldwin Investment Management LLC |
- Analyzing AbbVie's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether AbbVie's stock is overvalued or undervalued compared to its peers.
- Examining AbbVie's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating AbbVie's management team can have a significant impact on its success or failure. Reviewing the track record and experience of AbbVie's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of AbbVie's stock. These opinions can provide insight into AbbVie's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for AbbVie Stock Analysis
When running AbbVie's price analysis, check to measure AbbVie's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AbbVie is operating at the current time. Most of AbbVie's value examination focuses on studying past and present price action to predict the probability of AbbVie's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AbbVie's price. Additionally, you may evaluate how the addition of AbbVie to your portfolios can decrease your overall portfolio volatility.